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Quantifying the Arterial Input Function*
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oMeasurement of absolute myocardial blood flow
(MBF) and coronary flow reserve (CFR) is of great
importance clinically. To make such measurements
quantitatively, one must also measure the arterial
input function (AIF). Many studies, including the
one reported by Vasquez et al. (1) in this issue of
iJACC, which focuses on rubidium-82 (82Rb), have
sought optimal ways to measure the AIF for a
variety of tracers. Knowledge of the AIF is critical,
not just to determine MBF and CFR, but also to
measure other parameters of myocardial physiology
(e.g., glucose and oxidative metabolic rates). It is
worthwhile, therefore, to further reflect on the AIF.
What is it? How is it used? How can it be
measured? How might errors in its measurement
affect clinical decisions?
See page 559
The AIF is simply the concentration of the
radiotracer in the arterial blood measured over time.
This arterial blood is the only supply of tracer to the
myocardium and to most other organs in the body.
The amount of tracer delivered to the myocardium
is influenced by a complex set of factors: How much
was injected? For a venous injection, how much
makes it through the lungs? What fraction of the
arterial blood flows to the myocardium compared
with other organs? How much is removed from the
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they have no relationships relevant to the contents of this paper to
disclose.rterial blood by other organs and is trapped or
leared from the body? How much of the tracer that
eaches various tissues is then released back into the
enous blood, and thus can recirculate? (We ignore
ere the potential problems associated with labeled
etabolic products.) By measuring the AIF we can
void answering these questions. The AIF tells us di-
ectly how much and for how long the tracer was
vailable to the myocardium. Without some knowledge
f the AIF, it is impossible to make accurate physiolog-
cal measurements from radiotracer experiments.
There are many tracers that can be used to
easure myocardial perfusion. A “perfect” tracer
ould be one that the myocardial cells could com-
letely extract from the arterial blood. Water
H2
15O) is an example of a tracer that is nearly
00% extracted. Ideally, for imaging purposes, the
racer would also be trapped once it entered the
yocardium, but water washes out rapidly, propor-
ional to MBF. Radioactive labeled microspheres,
n the other hand, would be an example of a
perfect” tracer with ideal imaging properties.
To determine MBF with such a perfect, trapped
racer, one need only measure the amount of tracer
aken up by the myocardial region of interest and
hen divide by the total amount available to the
yocardium. The total amount available is simply
he area under the AIF curve (AUC). This ratio of
ptake divided by the AUC gives the absolute MBF
ml/min to the region or ml/min/g tissue). This
ivision by the AUC is also the basis for the
implified computation of MBF and CFR of
asquez et al. (1).
For the special case of a “perfect” tracer, it is easy
o see how errors in the AIF would produce errors
n the measurement of MBF. A certain percentage
f underestimation of the AUC causes the MBF to
e too high by that same percentage, and vice versa.
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570Absolute MBF values have rarely been used
clinically, although this is changing as it becomes
easier to make such measurements. CFR, however,
is known to be of great practical importance. Be-
cause CFR is simply the ratio of MBF during stress
to MBF at rest, if a percentage error is made in the
AIF at rest and the same percentage error is made at
stress, the errors will cancel out. Therefore, any
systematic underestimates or overestimates of the
AUC do not matter, providing the same percentage
error is made at both rest and stress. Random errors,
or nonsystematic errors, however, will affect both
MBF and CFR.
What about real-world, nonideal tracers like
82Rb or 13N-ammonia (13NH3)? For these tracers,
the calculation of MBF is more complex and usually
(but not in the case of Vasquez et al. [1]) requires
not just the AIF AUC, but an accurate measure-
ment of the shape of the AIF (i.e., how it changes
with time).
Measuring the AIF. To see how systematic and non-
ystematic errors can arise, consider how the AIF is
easured. The most direct way to measure the AIF
ould seem to be by drawing blood over time from
n arterial catheter and determining the blood
ctivity. There are machines that perform these
teps automatically (2). These are used in research
nvironments and are clearly not clinically practical.
n addition, this approach is not as free of error as
t sounds. Unless the rate of blood drawn is very
igh, there will be dispersion and delays in the
easured activity compared with the true arterial
ctivity. In addition, a cross-calibration is needed to
onvert counts measured from the collected blood
o counts measured from the scanner. The obvious
oninvasive way to measure the AIF is to use the
mage data. Blood pool regions including the left
entricular (LV) cavity, the left atrial (LA) cavity,
nd the aorta (ascending and/or descending) are all
ithin the field of view of a cardiac scan and contain
rterial blood. A dynamic set of images acquired
rom the time of injection on can be used to
roduce an image-derived input function (IDIF) to
stimate the AIF. Simply place a volume of interest
VOI) over the blood pool and create a time activity
urve (TAC); that curve will be the AIF. The IDIF
ethod avoids any need for cross-calibration; the
ctivity concentrations measured by the scanner are
sed for both the AIF and the tissue. What then are
he problems with using such image-based meth-
ds? There are 3 principal pitfalls: 1) count rate
imitations of the scanner; 2) statistical fluctuations;
nd 3) the partial volume (PV) effect. rThe effect of count rate on the AIF. Clinical 82Rb or
13NH3 images are usually taken after the blood pool
activity has decreased considerably, 90 to 120 s after
the end of injection for 82Rb and several minutes or
ore for 13NH3. By then, the activity has decayed
nd distributed throughout the body, greatly reduc-
ng the activity in the scanner field of view. To
easure the AIF, however, the dynamic scan must
egin at the start of injection because the entire
ose (as much as 50 mCi for 82Rb) passes through
he heart. This can cause very high count rates,
equiring significant corrections for accidental co-
ncidences and dead time. In older 2-dimensional
canners (i.e., septa in), many but not all scanners
an perform such large corrections accurately. In
odern 3-dimensional only (septa out) scanners,
he dose delivered must be significantly reduced.
hus, although 3-dimensional scanners provide
igh sensitivity, which is very beneficial when count
ates are low, the count rate limitation requires
ower activity injections for accurate measurement
f the AIF.
Statistical ﬂuctuations. The second problem with
accurate AIF measurements is due to counting
statistical fluctuations. For determining MBF from
the “perfect” tracer mentioned earlier, all one needs
is the AUC (i.e., total integrated activity under the
AIF). This total area, although not free of statistical
fluctuations, is less influenced by them than point-
by-point TACs. For 82Rb and 13NH3, however, the
shape of both the AIF and the tissue curves is
usually important. If one uses a small VOI for the
IDIF, then these statistical fluctuations can be
large. For example, if the AIF was measured 3 times
using an LV, LA, or aortic VOI, the 3 IDIFs would
differ slightly in height, shape, and area due to
statistical fluctuations alone, even if all other factors
were equal. Fortunately, if the AIF is used in a
kinetic model, the noise effects are mitigated by the
integrating nature of the model equations (see the
following), or by integration if the AUC is used.
Statistical fluctuations can also be minimized by
making the VOI larger, encompassing as much of
the blood pool (LV cavity, aorta, or LA cavity) as
possible. Unfortunately, this strategy produces
other errors caused by the so-called PV effect.
The PV effect. To better understand the PV effect,
onsider a structure like the aorta, which might
ave a diameter of 2 to 3 cm. With a perfect
canner, a cross-sectional image would show uni-
orm activity concentration across the aorta. Real
ardiac images, however, usually have reconstructed
esolutions of no better than 8 mm full width at half
r
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571maximum (FWHM), often much larger. This will
cause the aorta image to blur, smearing counts from
inside to outside the aorta’s anatomic borders,
reducing the measured peak activity. The blurring
does not reduce the total activity; it simply smears it
into a larger volume. A VOI drawn around the
aorta will therefore measure less than the true
concentration of activity. The fraction of the true
activity concentration measured in a VOI is called
the recovery coefficient or simply the percentage of
recovery. In addition, if there were any structures
containing activity near the aorta’s anatomic bor-
ders (e.g., the liver in the descending aorta), counts
from these structures would blur into the aorta. If
there were no activity-containing structures outside
the aorta, one could draw a very large VOI and
capture all the counts originally in the aorta, before
blurring. But because the AIF is a measure of the
activity concentration, one would have to divide this
total activity by the true aorta volume to get an
accurate AIF.
This unwanted mixing of counts from inside and
outside a structure is the hallmark of the PV effect.
A rule of thumb to minimize the PV effect is to
keep the VOI’s edge, ideally, at least 1.5  the
esolution distance from the edge of the structure.
y resolution distance, we mean the actual recon-
tructed image resolution, measured as FWHM,
ot the resolution quoted by the manufacturer.
ypical clinical cardiac scans have an FWHM
econstructed resolution on the order of 8 to 12
m. Therefore, the LA and, to a lesser extent, the
V cavities, which are large structures, can have
arger VOIs drawn on them than the aorta before
ncurring PV effects. VOIs drawn on the aorta, on
he other hand, will have smaller percentage of
ecovery, unless the VOI is small and/or the recon-
tructed resolution is high.
Because activity mixes in all directions, the PV
ffect can produce insidious errors in the AIF.
hortly after injection, the activity outside the blood
ool region is usually comparatively low, so the PV
ffect causes the activity measured with too large a
OI to be underestimated due to spill-out. The
ercentage of recovery can be kept high by using a
maller VOI, drawing it on multiple slices to
inimize the statistical fluctuations. At late times,
he situation for the LV cavity is reversed; the
yocardium is hot, so an oversized LV VOI may
verestimate the AIF because counts from the
yocardium blur into the VOI (spill-in). For a
iven size VOI, the PV effect will be worse for the
orta than for the LV or LA cavities because theorta is smaller in diameter. At late times, however,
either the aorta nor the LA is as close to the hot
yocardial walls as the LV. In addition, the LV
alls contract, causing additional blurring into an
V VOI. For this reason, when one uses an LV
avity VOI, one usually restricts it to the basal
spect, where contraction is limited. The left atrium
as very little contraction (and low myocardial
ptake) by comparison. Note that the aorta can
ulsate with each heartbeat, causing a worsening of
ffective resolution. In theory, the aortic PV effect
apart from motion effects) can be corrected if one
nows the real resolution of the images and the
xact sizes of the VOI and of the object (e.g., the
orta) (3). Unfortunately, the motion component of
he resolution is more difficult to measure. None-
heless, the aorta has been successfully used to
easure the AIF after PV corrections. Its location
an be defined using early scan data and its size
rom a computed tomography scan.
One useful approach to minimizing the PV effect
n the AIF is worth mentioning because it works
ell for 82Rb and 13NH3 scans. One acquires the
dynamic part of the scan at the highest possible
resolution (e.g., very little filtering). These images
often look very noisy and are nearly useless for
reading or defining VOIs; this does not matter
because they will be used only to make TACs. To
define the VOIs, one can use smoother images (e.g.,
summed, smoothed early data for the blood pool,
and smoothed late clinical images for the myocar-
dial VOIs). Although these VOIs might have a
poor percentage of recovery for these smoothed
images, they can be applied to the higher resolution,
noisy data to make the AIF and the tissue TACs
with a higher percentage of recovery.
Effect of AIF errors in MBF models. We spoke only of
perfect” tracers earlier, although the same PV and
tatistical effects occur for real-world tracers. The
ffects of errors in the AIF on 82Rb and 13NH3
MBF are more complicated. These tracers are not
completely extracted by the myocardium, and the
extracted molecules may wash out. To account for
this requires a mathematical/physiological model.
Typically, the AIF is fed into the model and is fit to
the measured tissue TAC to calculate a value
proportional to MBF. The proportionality factor is
the fraction of the tracer that is extracted by the
tissue; that is, the model yields flow (F) times
extraction fraction (E): F  E. The extraction
fraction is itself influenced by MBF, being greater
at low flows (when the low flow gives the tracer
more time to enter the myocardial cells) than at
m
f
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572high flows. Unfortunately, it is difficult to deter-
mine E, so that one must usually rely on animal
models or other ancillary information to estimate E
(4). For CFR, a ratio of MBF at stress to MBF at
rest is needed. One might hope that the Es would
cancel out, but because E is flow dependent, this is
not the case.
There are 2 tracer kinetic models commonly used to
measure flow from 82Rb and 13NH3: a 1-compartment
(1C) model (4) and a 2-compartment (2C) model (5)
(Vasquez et al. [1], however, do not rely on these
models). In general, these models behave in many
of the same ways as described earlier for the
“perfect” tracers. If the AIF is systematically under-
estimated, the flow value is overestimated and vice
versa. The 2C model arguably describes the physi-
ology most accurately. Unfortunately, in physics as
in life, one rarely gets “something for nothing.” The
extra information gained from the 2C model comes
at a price; flow values are more susceptible to noise
in the AIF (and noise in the tissue TAC). For a
given amount of noise in the AIF and tissue TAC,
the 1C model produces less variability in flow. For
this reason, the 1C model is more often used for
82Rb. In addition, errors in measuring the shape of
the AIF (due to time-dependent spill-out and
spill-in) have a more complicated effect on MBF
errors.
The tissue TAC is also affected by noise and PV
effects, but in the reverse manner as the AIF; the
tissue TAC is often too high at early times (due to
spill in from the hot blood pool) and too low at late
times. One important advantage of using mathe-
matical models to estimate MBF is that these
models can often incorporate corrections for spill-in
and spill-out of the tissue TACs (4,5). For 82Rb
and 13NH3, such corrections can be quite useful in
inimizing errors in MBF, but they do not correct
or inaccuracies in the AIF.
Previous research. These cited facts have been used
by many investigators searching for an optimal way
to draw VOIs to determine the AIF for various
tracers. Some (6) compared using different size
VOIs in the left ventricle, the left atrium, and the
ascending and descending aorta, concluding that for
18F-fluorodeoxyglucose, the aortic arch gave the
best agreement with the lowest variability, des-
pite the fact that the left ventricle and left atrium
gave higher peak AIF values. Others (7) compared
the left atrium, left ventricle, and thoracic aorta for
H2
15O, and found that the left atrium seemed
optimal (they did not examine the aortic arch). The
effect of AIF errors on MBF caused by myocardialspill-in has also been studied for 13NH3 at both rest
and stress (8). Some papers have compared various
VOI sizes and locations using the MBF or CFR
computed with actual arterial sampling as their gold
standard. The paper by Vasquez et al. (1) examines
VOI selection for 82Rb without a gold standard
such as arterial sampling. Instead (using a 1-pixel
VOI), they assume that the VOI having the largest
AIF (as measured by its 2-min AUC) must be the
“correct” value. Vasquez et al. (1) compare MBF
and CFR from other VOIs with this “correct” value.
The assumption that the largest AUC is the “cor-
rect” one requires that VOI size and location and
image resolution be such that the percentage of
recovery is 100%. In other words, this approach
assumes that there is no spill-in or spill-out con-
tamination and that the largest 1-pixel AUC is not
the largest simply due to statistical fluctuations
(assumed to be small because the AUC is used).
They refer to a previous phantom study to assess
percentage of recovery, although the current paper
does not explicitly state the reconstructed resolution
of their images. If the authors’ assumptions are true,
one could try many VOIs and select the one with
the largest 2-min AUC. Of course readers would
need to assure themselves that the assumptions
were valid for their own imaging systems and
protocols.
Conclusions. Many studies suggest that accurate
measurements of AIF and MBF are quite possible
in clinical situations, and commercial software has
even been developed. However, there are many
pitfalls. These pitfalls are slightly different for dif-
ferent tracers and different methods of computing
flow and have different impacts on rest versus stress
studies. Thus, it is important to choose an appro-
priate AIF method within the context of the MBF
model and analysis that are used. But armed with an
understanding of the underlying difficulties, it is
possible to make accurate measurements of MBF
and CFR with a variety of tracers. It is important, in
both research and clinical settings, that the “con-
sumers” of positron emission tomography MBF and
CFR measures have a good appreciation of the
limitations and caveats of these remarkable quanti-
tative in vivo assays.
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